As noted in the RFP, fund distribution is contingent upon a signed contract with the AAMC and documentation of current IRB approval of the project. We will send the contract to you under separate cover. I will also contact you to arrange a discussion to this end, and to organize a meeting around the AAMC evaluation of the project.
Review Committee Comments
Project Title: The HEART Pathway: Bridging the Gap between Operations, Research and Education PI: Simon Mahler, MD, MS; Assistant Professor, Department of Emergency Medicine; Wake Forest University Health Services
Qualifications of the leadership and investigative team
Dr. Simon A. Mahler is well qualified to head this program. He is an established scientist in the area of cardiac assessment in the ED and has published several articles. He has research support from AHA and NIH on cardiac assessment. Dr. C. Miller, the coinvestigator is also the director of clinical research / ED. Thus, the team is well experienced with a track record and departmental success.
Rigor of study design and analytic plan
The weak prepost design is well justified and need for it documented. This is a carefully designed implementation study and the analytic plan is appropriate and straightforward. Power estimates are satisfactory. Will look at primary outcomes in 30 days for cardiac events, secondary outcomes analysis of utilization of cardiac testing, LOS, ED visits. Hospitalizations will be reviewed for both inpatient and ovservational status. Strong evidence base for intervention. Some of death data not specified (at home, out of area).
Likelihood that approach will be innovative and outcomes will have impact
This is not a highly innovative approach, the Heart Pathway has been around for some time. What is significant is the incredible institutional support to train/educate and support this program. The impact at Wake Forest will be significant and long lasting if the outcomes data supports the program. The project could be a model for organizational commitment to solving an important clinical problem that controls cost and provides acceptable safe care. The ideas behind it are solid and the premise that we should not be overtesting lowrisk patents is compelling.
